Targeted Oncology

Targeted Healthcare Communications is at the forefront of the increasing interest in cancer-related products within precision medicine. We proudly hold the distinction of being the first publisher to feature a peer-reviewed journal dedicated to these innovative products. Our offerings include a specialized website, two journals, and a variety of multichannel programs that all concentrate on precision medicine in the field of oncology. Our publication, Targeted Therapies in Oncology™, is committed to equipping oncology healthcare professionals with the latest research, data, and treatment methods related to molecular and immune system targets that can enhance patient outcomes in cancer care. We aim to make the latest developments in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted treatments more accessible for clinical application. The Journal of Targeted Therapies in Cancer™ focuses on elevating cancer patient care by publishing peer-reviewed clinical articles that delve into advancements in cancer targets and targeted therapies, along with their practical applications. Our goal is to broaden oncologists' understanding of biomarkers, pathways, diagnostics, immunotherapy, and targeted therapies, while also providing strategies for personalizing treatment to achieve better patient outcomes. TargetedOnc.com™ is a distinctive resource that emphasizes molecular biology, featuring expert insights on research, management, and treatment. This oncology-centered website is dedicated to providing content that highlights precision medicine in the field. As cancer research shifts towards systems biology and molecular irregularities, many oncologists face the challenge of keeping their knowledge up to date with the evolving landscape of cancer therapeutics.

International, National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#339713

United States

#144675

Health/Health Conditions and Concerns

#337

Traffic sources

Monthly visitors

Articles

Nivolumab/Relatlimab Shows Intracranial Activity in Melanoma Brain Mets

23 hours ago | targetedonc.com | Tim Cortese

Nivolumab (Opdivo) combined with relatlimab displayed intracranial effectiveness in patients with melanoma brain metastases whose disease had progressed despite prior anti-PD-(L)1 therapy. However, additional data is necessary to firmly establish its efficacy, according to findings from the phase 1/2a RELATIVITY-020 trial (NCT01968109) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Larotrectinib Shows Durable Responses, Safety in TRK Fusion Thyroid Carcinoma

1 day ago | targetedonc.com | Jordyn Sava

An updated analysis on larotrectinib (Vitrakvi) for patients with TRK fusion thyroid carcinoma showed compelling data on the agent’s efficacy and safety, including a high and durable response rate and a manageable safety profile.1 Of the 31 patients included in the analysis, the overall response rate (ORR) was 65% (95% CI, 45%-81%), which included 3 (10%) complete responses, 17 (55%) partial responses (PR), 5 (16%) cases of stable disease (SD), 4 (13%) cases of progressive disease (PD), and 2...
FINER Trial: Ipatasertib Combo Extends PFS in ER+/HER2- Breast Cancer

2 days ago | targetedonc.com | Kyle Doherty

Ipatasertib plus with fulvestrant (Faslodex) led to significantly longer progression-free survival (PFS) compared with placebo and fulvestrant in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer following disease progression on frontline CDK4/6 inhibitor and aromatase inhibitor (AI) therapy, according to data from the phase 3 FINER trial (NCT04650581) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
ICT01 Boosts AML Remission and Survival in EVICTION Trial

3 days ago | targetedonc.com | Jordyn Sava

Results from the ongoing phase 1/2a EVICTION study (NCT04243499) of ICT01 in combination with azacitidine and venetoclax (Venclexta) for newly diagnosed acute myeloid leukemia (AML) are encouraging, demonstrating a complete response (CR) rate of 74% in older/unfit patients. This result nearly doubles the historical CR rates observed with azacitidine and venetoclax alone.
177Lu PSMA-617 Improves rPFS in mHSPC: PSMAddition Trial

3 days ago | targetedonc.com | Jordyn Sava

Lutetium-177 (177Lu) vipivotide tetraxetan (177Lu PSMA-617; Pluvicto) in combination with hormone therapy provided a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) compared with hormone therapy alone, according to findings from the interim analysis of the phase 3 PSMAddition trial (NCT04720157).1 A promising...
Adjuvant Encorafenib/Binimetinib Reduces Recurrence in BRAF-Mutant Melanoma

3 days ago | targetedonc.com | Ashley Chan

Encorafenib (Braftovi) plus binimetinib (Mektovi) was generally well tolerated and showed promise for adjuvant BRAF/MEK inhibition to reduce recurrence risk in patients with high-risk, stage IIB/C BRAF V600–mutated melanoma, according to data from the primary analysis of the phase 3 EORTC-2139-MG/Columbus-AD trial (NCT05270044) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 In the intention-to-treat (ITT) population (n = 110), the 12-month recurrence-free...
Cobolimab/Dostarlimab Combo Improves Responses in High-Risk Melanoma

3 days ago | targetedonc.com | Kyle Doherty

Adding cobolimab to dostarlimab-gxly (Jemperli) was tolerable and led to better efficacy vs dostarlimab alone in neoadjuvant high-risk resectable melanoma, according to data from the phase 2 NEO-MEL-T trial (NCT04139902) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
DKRd Improves Efficacy in Newly Diagnosed Multiple Myeloma

3 days ago | targetedonc.com | Tim Cortese

The addition of daratumumab (D; Darzalex) to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) led to better efficacy without compromising safety for the treatment of patients with newly diagnosed multiple myeloma, according to results from the phase 2 ADVANCE trial (NCT04268498) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 In the intention-to-treat population, the minimal residual disease (MRD) negativity of 10-5 assessed by...
ctDNA Undetectability Predicts Better Outcomes in Cervical Cancer

3 days ago | targetedonc.com | Ashley Chan

An exploratory circulating tumor DNA (ctDNA) analysis from the phase 3 CALLA trial (NCT03830866) demonstrated that the risk of disease progression or death was reduced by at least 95% in patients with locally advanced cervical cancer who received durvalumab (Imfinzi) plus chemoradiotherapy (CRT) or CRT plus placebo who had undetectable ctDNA at the start of cycle 6. Additionally, low ctDNA at baseline was associated with improved survival outcomes in both arms compared with high ctDNA.
Neoadjuvant Nivolumab & Chemo Improves NSCLC Overall Survival

4 days ago | targetedonc.com | Kristi Rosa

Neoadjuvant nivolumab (Opdivo) in combination with chemotherapy elicited a statistically significant and clinically meaningful overall survival (OS) improvement vs chemotherapy alone in patients with resectable non–small cell lung cancer (NSCLC), according to findings from the phase 3 CheckMate-816 study (NCT02998528) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 At a median follow-up of 68.4 months, the median OS was not reached (NR) with nivolumab...